Driving strategy to results
Advancy partners with investors and corporates to unlock growth across the entire Pharmaceuticals and Medtech value chains, from upstream ingredients and device components to finished pharmaceutical and medtech products, encompassing B2B platforms, distribution models, and patient care pathways.
Our expertise covers Pharma Services (CDMO, CRO and other Clinical Services), Specialty Pharma, Generics, and OTC,
as well as all major medtech categories, including IVD, orthopedics, cardiovascular, surgical devices, etc.
We stand out by going the extra mile: Our approach is specialized and hands-on, with expert senior leadership involved in each engagement to ensure technical rigor and actionable outcomes. Whether supporting buy and sell-side due diligence, driving operational transformations, or defining growth strategies, we bring unmatched expertise on market, commercial and industrial operations. Our work is grounded in deep scientific fluency and we maintain a wide network of experts in medical, R&D, commercial or manufacturing functions.
With close to 150 projects delivered annually for top-tier private equity firms and corporate clients, Advancy combines investor understanding with operational depth across every segment of the value chain.
We support investors and corporate leaders throughout the full investment and value creation cycle in the healthcare sector:
We work with investors and global leaders in APIs, drug product manufacturing (solid dose, sterile injectables, inhalation, etc.), pharmaceutical ingredients (e.g., excipients), and service providers (CROs, clinical logistics, packaging).
Our engagements span commercial and technical due diligence, capacity strategy, service offering design, and cost benchmarking to build competitive, resilient platforms in a rapidly evolving outsourcing landscape.
We support corporate clients and investors across B2B and B2C specialty pharma models, helping them assess acquisition targets, shape therapeutic focus, and evaluate product lifecycle opportunities.
Our engagements include M&A screening and diligence, licensing and BD strategy, and operational improvement initiatives, always informed by a clear understanding of regulatory constraints and go-to-market models.
We advise clients and investors in generics and branded generics on growth acceleration and industrial competitiveness.
Our projects typically address strategic positioning across key therapeutic areas, operational cost optimization, and procurement and manufacturing footprint decisions. We also support M&A strategy and asset screening to help clients stay ahead in this margin-sensitive space.
We support investors, ingredient suppliers, CDMOs, and brand owners operating across OTC and consumer health categories.
Our work spans new product development, go-to-market and retail channel strategy, consumer activation models, and M&A execution. We bring a detailed understanding of consumer trends, regulatory constraints, and branding levers across self-care, wellness, and preventive health segments.
We work with CDMOs, OEMs, and investors across the full medtech landscape, including diagnostic, therapeutic, surgical, orthopedic, cardiovascular and implantable technologies. Our projects cover due diligence, commercial strategy, portfolio expansion, and industrial optimization.
We tailor our approach to the technical, regulatory, and manufacturing complexity of each subsegment, and factor in the unique characteristics of medtech markets: faster innovation cycles, shorter product lifecycles, and limited IP protection.
We support investors and corporates across laboratory, analytical, and bioprocessing workflows, spanning equipment, consumables, and services. Our expertise includes commercial and operational due diligence, M&A screening, innovation scouting, and pricing strategy.
We help clients respond to changing scientific demands and capital deployment trends in research, bioprocessing, and quality control environments, while factoring the role of consolidated LST distribution channels in many segments.
Healthcare systems face increasing pressure to deliver better outcomes, improve access, and control costs, all while integrating evolution of the regulation and innovation.
Our teams combine deep sector expertise with a hands-on, co-creative approach to help our clients, corporates and investors, to navigate transformation (strategy, operations, network management, procurement, relation with key stakeholders), scale innovation at global and local level, and build resilient, people and patient-centric models that perform today and tomorrow.
